CoChat

Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC).

Munster, Pamela N., Hamilton, Erika Paige, Franklin, Catherine, Bhansali, Suraj, Wan, Kitty, Hewes, Becker, Juric, Dejan · 2014 · Journal of Clinical Oncology
Cited by 33

The DOI matches its Crossref record.

Abstract

533 Background: Postmenopausal women with advanced ER+ BC are usually treated with aromatase inhibitors (AIs) as first-line therapy but resistance eventually develops. Dysregulation of the PI3K pathway and cyclin D kinases 4 and 6 (CDK4/6) has been implicated in resistance to endocrine therapy. LEE011 (a selective CDK4/6 inhibitor) and BYL719 (an α-selective PI3K inhibitor) demonstrate clinical activity in ER+ BC as single agents. In ER+ BC xenograft models, LEE011 has demonstrated enhanced antitumor activity when combined with BYL719 and letrozole versus each agent alone, suggesting this combination may optimize treatment in ER+ BC. In the ongoing Phase Ib part of this study (NCT01872260), two doublet combinations, LEE011 + letrozole (Arm 1) and BYL719 + letrozole (Arm 2), and the triplet combination of LEE011 + BYL719 + letrozole (Arm 3), are explored in patients with ER+ BC. Methods: Postmenopausal women with locally advanced/metastatic ER+, HER2− BC not amenable to curative treatment by surgery/radiotherapy receive escalating doses of oral LEE011 QD (3-wks on/1-wk off) or BYL719 QD (continuous) and a fixed dose of letrozole QD (2.5 mg, continuous) in 28-day cycles. The primary objective is to estimate the MTD and/or RP2D of each combination by assessing DLTs in Cycle 1 using an adaptive Bayesian Logistic Regression Model (BLRM) guided by the escalation with overdose control (EWOC) principle. Secondary objectives include safety, PK and preliminary efficacy assessments. Results: As of Jan 31, 2014, 6 patients have been treated in Arm 1 (LEE011 600 mg + letrozole), and 1 DLT (G4 neutropenia) has been reported. Five patients have started treatment in Arm 2 (BYL719 300 mg + letrozole). Preliminary PK data are consistent with that for the respective single agents, with no evidence of drug–drug interactions. Conclusions: AIs are recommended as first-line endocrine therapy in postmenopausal patients with advanced ER+, HER2− BC, but most patients develop resistance. This is the first trial evaluating an AI in combination with a PI3K and CDK4/6 inhibitor in ER+, HER2− BC. Phase II will compare the preliminary antitumor activity of the doublets vs. triplet combinations. Clinical trial information: NCT01872260.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.32.15_suppl.533

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 33

Metadata

Authors
Munster, P. N., Hamilton, E. P., Franklin, C., Bhansali, S., Wan, K., Hewes, B., & Juric, D.
Venue
Journal of Clinical Oncology
Published
2014-05-20
Volume
32
Issue
15_suppl
Pages
533-533
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1470988277
Cited by
33
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC). https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.533
The paper
Munster, P. N., Hamilton, E. P., Franklin, C., Bhansali, S., Wan, K., Hewes, B., & Juric, D. (2014). Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.533

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.